|13th November 2020||Evan Loh||20,928||Open or private sale||$5.93||$124,103.04|
|12th November 2020||Evan Loh||75,000||Grant/award etc.||$0.00|
|29th October 2020||Evan Loh||39,479||Exercise of derivative||$4.30||$169,759.70|
|12th August 2020||Jeffrey S Glenn||4,500||Open or private purchase||$11.44||$51,465.15|
|12th August 2020||Jeffrey S Glenn||500||Open or private purchase||$11.28||$5,637.50|
|11th August 2020||Jeffrey S Glenn||5,000||Open or private purchase||$11.49||$57,463.50|
|3rd August 2020||Amit Sachdev||690||Open or private sale||$278.25||$191,992.50|
|3rd August 2020||Amit Sachdev||500||Open or private sale||$276.96||$138,480.00|
|3rd August 2020||Amit Sachdev||1,941||Exercise of derivative||$86.52||$167,935.32|
|3rd August 2020||Amit Sachdev||751||Open or private sale||$279.18||$209,664.18|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Eiger BioPharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of well-characterized drugs for life-threatening, rare and ultra-rare diseases.